α-Methyl-5-hydroxytryptophan

From The Right Wiki
Jump to navigationJump to search

α-Methyl-5-hydroxytryptophan
Clinical data
Other namesalpha-Methyl-5-hydroxytryptophan; alpha-Methyl-L-5-hydroxytryptophan; α-Me-5-HTP; α-Methyl-5-HTP; αM-5-HTP; alpha-Me-5-HTP; alpha-Methyl-5-HTP
Drug classTyrosine hydroxylase inhibitor; Serotonin receptor agonist
Identifiers
  • (2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)-2-methylpropanoic acid
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H14N2O3
Molar mass234.255 g·mol−1
3D model (JSmol)
  • C[C@](CC1=CNC2=C1C=C(C=C2)O)(C(=O)O)N
  • InChI=1S/C12H14N2O3/c1-12(13,11(16)17)5-7-6-14-10-3-2-8(15)4-9(7)10/h2-4,6,14-15H,5,13H2,1H3,(H,16,17)/t12-/m0/s1
  • Key:QNQKTYDMWUGLPA-LBPRGKRZSA-N

α-Methyl-5-hydroxytryptophan (α-Me-5-HTP) is a synthetic tryptamine derivative, an artificial amino acid, and a prodrug of α-methylserotonin.[1][2] It is the α-methylated derivative of 5-hydroxytryptophan (5-HTP), while αMS is the α-methylated analogue of serotonin.[1][2] Along with α-methyltryptophan (α-MTP), α-Me-5-HTP has been suggested for potential therapeutic use in the treatment of conditions thought by some authors to be related to serotonin deficiency, such as depression.[2] αMS is a non-selective serotonin receptor agonist, including of the serotonin 5-HT2 receptors, and has been described as a "substitute neurotransmitter" of serotonin.[2][3][4][5] However, whereas αMS itself is too hydrophilic to efficiently cross the blood–brain barrier, thus being peripherally selective, α-MTP and α-Me-5-HTP are able to cross the blood–brain barrier and, following transformation, deliver αMS into the brain.[2][6] Besides αMS, α-methylmelatonin can be formed in small amounts from α-Me-5-HTP.[7] In addition to their serotonergic activity, α-Me-5-HTP and αMS have been found to act as norepinephrine releasing agents similarly to α-methylphenylalanine and to other α-alkylated tryptamines.[8][9][10] Moreover, α-Me-5-HTP is also a tyrosine hydroxylase inhibitor similarly to α-methyltyrosine, as well as an aromatic L-amino acid decarboxylase (AAAD) inhibitor, and has been found to deplete levels of brain norepinephrine in animals, although not levels of brain dopamine.[2][11][8][12][13] Because of these actions, α-Me-5-HTP shows antihypertensive effects and reduces locomotor activity in animals.[12]

See also

References

  1. 1.0 1.1 "alpha-Methyl-5-hydroxytryptophan". PubChem. Retrieved 8 October 2024.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Sourkes TL (1991). "Alpha-methyltryptophan as a therapeutic agent". Prog Neuropsychopharmacol Biol Psychiatry. 15 (6): 935–938. doi:10.1016/0278-5846(91)90020-2. PMID 1763198.
  3. Maroteaux L, Ayme-Dietrich E, Aubertin-Kirch G, Banas S, Quentin E, Lawson R, et al. (February 2017). "New therapeutic opportunities for 5-HT2 receptor ligands" (PDF). Pharmacol Ther. 170: 14–36. doi:10.1016/j.pharmthera.2016.10.008. PMID 27771435. alpha-methyl-5-HT is a non-selective nearly full agonist at 5-HT2 receptors with similar affinity to 5-HT2A 5-HT2B and 5-HT2C receptors (Jerman, et al., 2001; Knight, et al., 2004; Porter, et al., 1999).
  4. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, et al. (2001). "Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists". Pharmacol Biochem Behav. 69 (3–4): 643–652. doi:10.1016/s0091-3057(01)00552-4. PMID 11509227.
  5. Ismaiel AM, Titeler M, Miller KJ, Smith TS, Glennon RA (February 1990). "5-HT1 and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin". Journal of Medicinal Chemistry. 33 (2): 755–758. doi:10.1021/jm00164a046. PMID 2299641.
  6. Diksic M, Young SN (September 2001). "Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan". J Neurochem. 78 (6): 1185–1200. doi:10.1046/j.1471-4159.2001.00536.x. PMID 11579128.
  7. Montine TJ, Missala K, Sourkes TL (January 1992). "Alpha-methyltryptophan metabolism in rat pineal gland and brain". J Pineal Res. 12 (1): 43–48. doi:10.1111/j.1600-079x.1992.tb00024.x. PMID 1564632.
  8. 8.0 8.1 Lahti RA, Platz PA, Heinzelman RV (July 1969). "Effects of alpha-methyl-5-hydroxytryptophan and alpha-methyl-5-hydroxytryptamine on norepinephrine in mouse myocardium". Biochem Pharmacol. 18 (7): 1601–1608. doi:10.1016/0006-2952(69)90147-6. PMID 5306701.
  9. Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
  10. Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, et al. (October 2014). "Alpha-ethyltryptamines as dual dopamine-serotonin releasers". Bioorganic & Medicinal Chemistry Letters. 24 (19): 4754–4758. doi:10.1016/j.bmcl.2014.07.062. PMC 4211607. PMID 25193229.
  11. Murphy GF, Sourkes TL (May 1961). "The action of antidecarboxylases on the conversion of 3,4-dihydroxyphenylalanine to dopamine in vivo". Arch Biochem Biophys. 93 (2): 338–343. doi:10.1016/0003-9861(61)90276-4. PMID 13726974.
  12. 12.0 12.1 Tabei R, Spector S, Louis WJ, Sjoerdsma A (July 1969). "Antihypertensive and noradrenaline-depleting effects of alpha-methyl-5-hydroxytryptophan in the rat". Eur J Pharmacol. 7 (1): 39–44. doi:10.1016/0014-2999(69)90160-5. PMID 5307150.
  13. Dominic JA, Moore KE (December 1969). "Behavioral and catecholamine depleting effects of alpha-methyl-5-hydroxytryptophan". Eur J Pharmacol. 8 (3): 292–295. doi:10.1016/0014-2999(69)90037-5. PMID 5308817.